Focuses on the development of therapeutic projects and medical innovations for the treatment of infectious diseases and other unmet medical needs.
Aptorum Group Limited is a dynamic biopharmaceutical company actively involved in the discovery, development, and commercialization of innovative therapeutic products aimed at combatting infectious diseases and cancer. Established in 2010 and headquartered in London, United Kingdom, Aptorum operates across two primary segments: Therapeutics and Non-Therapeutics. Within its robust pipeline, notable candidates include SACT-1 for neuroblastoma and various cancer types, SACT-COV19 targeting coronavirus disease, and ALS-4 designed to address bacterial infections caused by staphylococcus aureus, including MRSA. Additionally, ALS-1 targets viral infections caused by influenza virus A, highlighting Aptorum's broad therapeutic focus.
Aptorum Group is also advancing ALS-2/3 for gram-positive bacterial infections, RPIDD for pathogen molecular diagnostics, and NativusWell DOI (NLS-2), a dietary supplement. The company's diversified portfolio extends to NLS-1 for endometriosis treatment, DLS-1+2 for NSCLC with mutation, DLS-3 for autoimmune diseases, and CLS-1 for obesity management. Aptorum's innovative approach includes systematic screening of existing approved drug molecules and leveraging microbiome-based research platforms to discover new therapeutic assets across neurology, gastroenterology, metabolic disorders, women's health, and other disease areas.
In addition to its research initiatives, Aptorum Group operates a medical clinic, underscoring its commitment to advancing healthcare solutions. With a strategic focus on therapeutic and diagnostic advancements, Aptorum Group continues to push boundaries in biopharmaceutical innovation to address unmet medical needs globally.